Current Report Filing (8-k)
February 03 2020 - 4:36PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): February
3, 2020
InVivo Therapeutics Holdings Corp.
(Exact Name of Registrant as Specified in
Charter)
Nevada
|
|
001-37350
|
|
36-4528166
|
(State or Other Jurisdiction
of Incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
One Kendall Square, Suite B14402
Cambridge, MA 02139
(Address of Principal Executive Offices)
(Zip Code)
Registrant’s telephone number, including
area code: (617) 863-5500
N/A
(Former Name or Former Address, if Changed
Since Last Report)
Check the appropriate box below if the Form 8-K filing
is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General
Instruction A.2. below):
¨ Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant
to Section 12(b) of the Act:
Title of each class
|
|
Trading symbol(s)
|
|
Name of each exchange on which
registered
|
Common Stock, $0.00001 par value per share
|
|
NVIV
|
|
The Nasdaq Capital Market
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of
the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 8.01 Other Events
On February 3,
2020, the Board of Directors of InVivo Therapeutics Holdings Corp. (the “Company”) approved a 1-for-30 reverse
stock split of the Company’s authorized shares of common stock, par value $0.00001 per share (the “Common Stock”),
accompanied by a corresponding decrease in the Company’s issued and outstanding shares of Common Stock (the “Reverse
Stock Split”), such that, following the consummation of the Reverse Stock Split, the number of authorized shares of Common
Stock shall be reduced from 500,000,000 to 16,666,667. The Reverse Stock Split will become effective at the effective time set
forth in the Certificate of Change to be filed with the Secretary of State of the State of Nevada (the “Certificate of
Change”). The Company expects to file the Certificate of Change following the completion of certain related administrative
processes, which the Company expects to be on or about February 10, 2020, and anticipates that the effective time of the Reverse
Stock Split will be on or about 5:00 pm New York time on February 11, 2020, with the Common Stock trading on a post-split basis
under the Company's existing trading symbol, "NVIV," at the market open on February 12, 2020. Fractional shares resulting
from the Reverse Stock Split shall be rounded up to the nearest whole share, and all shares of Common Stock (including fractions
thereof) issuable upon the Reverse Stock Split to a given stockholder shall be aggregated for the purpose of determining whether
the Reverse Stock Split would result in the issuance of a fractional share. Pursuant to Section 78.209 of the Nevada Revised Statutes,
the Company’s Board of Directors may take action to effect the Reverse Stock Split by filing a Certificate of Change with
the Secretary of State of the State of Nevada without the consent of the Company’s stockholders.
Cautionary Note Regarding Forward-Looking Statements
Any statements contained in this Current Report on Form 8-K
that do not describe historical facts may constitute forward-looking statements within the meaning of the federal securities laws.
These statements can be identified by words such as “believe,” “anticipate,” “intend,” “estimate,”
“will,” “may,” “should,” “expect,” “designed to,” “potentially,”
and similar expressions. Any forward-looking statements contained herein are based on current expectations and are subject to a
number of risks and uncertainties. Factors that could cause actual future results to differ materially from current expectations
include, but are not limited to, risks and uncertainties relating to the proposed Reverse Stock Split and the administrative processes
related thereto. Additional risk factors are described in the Company’s Annual Report on Form 10-K for the fiscal year ended
December 31, 2018 and its other filings with the SEC, including quarterly reports on Form 10-Q and Current Reports on Form 8-K.
The Company does not undertake to update these forward-looking statements.
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
INVIVO THERAPEUTICS HOLDINGS CORP.
|
|
|
|
Date: February 3, 2020
|
By:
|
/s/ Richard Toselli
|
|
Name:
|
Richard Toselli
|
|
Title:
|
Chief Executive Officer
|
InVivo Therapeutics (NASDAQ:NVIV)
Historical Stock Chart
From Aug 2024 to Sep 2024
InVivo Therapeutics (NASDAQ:NVIV)
Historical Stock Chart
From Sep 2023 to Sep 2024